{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:52:13Z","timestamp":1790905933396,"version":"4.1.0"},"reference-count":160,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T00:00:00Z","timestamp":1194393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the last few years, there has been increasing focus on the impact of interventions on cardiovascular outcomes in patients with type 2 diabetes. Insulin resistance and hyperglycaemia often co\u2010exist with a cluster of risk factors for coronary artery disease, but the underlying mechanisms leading to the development of such vascular complications are complex. The over\u2010production of free radicals in patients suffering from diabetes results in a state of oxidative stress, which leads to endothelial dysfunction and a greater risk of atherosclerosis. Moreover, inflammatory factors which play a critical role in atherothrombosis and plaque rupture are often found to be at elevated levels in this patient population.<\/jats:p><jats:p>Thiazolidinediones (TZDs) are now routinely used to manage glucose levels, and have been suggested to influence other cardiovascular risk factors and therefore the pathways leading to macrovascular events. Consequently, recent studies have investigated the anti\u2010inflammatory and anti\u2010atherogenic properties of TZDs. The data available up to the present time, in the context of the emerging cardiovascular outcome profiles of rosiglitazone and pioglitazone, will be discussed here. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dmrr.790","type":"journal-article","created":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T16:50:17Z","timestamp":1194454217000},"page":"14-26","source":"Crossref","is-referenced-by-count":93,"title":["Thiazolidinediones as anti\u2010inflammatory and anti\u2010atherogenic agents"],"prefix":"10.1002","volume":"24","author":[{"given":"Antonio","family":"Ceriello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,11,7]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1615"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200606010-00003"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X112723"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.12.S1.60"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2006.00077.x"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1690453"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-200108000-00002"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.53.082901.104018"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.70.1.341"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031315"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.266"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250100031"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041001"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X36440"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.3.235"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0931-5"},{"key":"e_1_2_9_18_2","first-page":"328","article-title":"Reactive oxygen species in tissue injury","volume":"41","author":"de Groot H","year":"1994","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.2007.S110"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0012-z"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119751"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000165070.46111.9F"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23354"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000122852.22604.78"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/34178"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01946-5"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0793com"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000072088"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000094411.98127.5F"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200112000-00008"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022138519281"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00718.2003"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00430.2002"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1683"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:29:1:143"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.549618"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-2226"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.9.2493"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fjc.0000187176.13403.05"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.03.041"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000244955.39491.88"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.19.2097"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.143.3.8662"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.10.007"},{"key":"e_1_2_9_45_2","first-page":"1040","article-title":"Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats","volume":"117","author":"Dong FQ","year":"2004","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-2174"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-870322"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.06.025"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2609"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.7.1547"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000025403.20953.23"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2007.01767.x"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000176192.16951.9a"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.9.778"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0648"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.7.7810"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000165072.01672.21"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2004.11.027"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02331"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.55.03.06.db05-0832"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.10.2662"},{"key":"e_1_2_9_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345545"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(00)00327-2"},{"key":"e_1_2_9_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01776.x"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.12.035"},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000124890.40436.77"},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000195790.24531.4f"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.05.027"},{"key":"e_1_2_9_70_2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1160\/TH03-06-0384","article-title":"Direct attenuation of plasminogen activator inhibitor type\u20101 expression in human adipose tissue by thiazolidinediones","volume":"91","author":"Zirlik A","year":"2004","journal-title":"Thromb Haemost"},{"issue":"3","key":"e_1_2_9_71_2","first-page":"32","article-title":"Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis","volume":"25","author":"Verges BL","year":"1999","journal-title":"Diabetes Metab"},{"key":"e_1_2_9_72_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.7.1231"},{"key":"e_1_2_9_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(07)70213-6"},{"key":"e_1_2_9_74_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000146094.59640.13"},{"key":"e_1_2_9_75_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1432"},{"key":"e_1_2_9_76_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.CIR.102.3.313","article-title":"Common carotid artery intima media thickness and brain infarction","volume":"102","author":"Touboul P\u2010J","year":"2000","journal-title":"Circulation"},{"key":"e_1_2_9_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.28.5.999"},{"key":"e_1_2_9_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050024"},{"key":"e_1_2_9_79_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.535484"},{"key":"e_1_2_9_80_2","unstructured":"Trial identifier NCT00225264. Available at:www.ClinicalTrials.gov. Accessed October 13 2006."},{"key":"e_1_2_9_81_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.21.joc60158"},{"key":"e_1_2_9_82_2","unstructured":"Trial identifier NCT00225277. Available at:www.ClinicalTrials.gov. Accessed October 13 2006."},{"key":"e_1_2_9_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"e_1_2_9_84_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.12.6.530"},{"key":"e_1_2_9_85_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27196"},{"key":"e_1_2_9_86_2","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200404020-00003"},{"key":"e_1_2_9_87_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.8.1476"},{"key":"e_1_2_9_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30503-3"},{"key":"e_1_2_9_89_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1018778"},{"issue":"1","key":"e_1_2_9_90_2","first-page":"101A","article-title":"The resistance to nitric oxide inhibition of platelet aggregation is due to decreased phosphorylation of rap 1B in platelets of NIDDM compared with control subjects","volume":"43","author":"Nolan RD","year":"1994","journal-title":"Diabetes"},{"key":"e_1_2_9_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-6980(00)00059-9"},{"key":"e_1_2_9_92_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.9.1494"},{"key":"e_1_2_9_93_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200620040-00004"},{"issue":"1","key":"e_1_2_9_94_2","first-page":"IV6","article-title":"Established and emerging plasma biomarkers in the prediction of first atherothrombotic events","volume":"109","author":"Ridker PM","year":"2004","journal-title":"Circulation"},{"key":"e_1_2_9_95_2","first-page":"331","article-title":"Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1","volume":"13","author":"Juhan\u2010Vague I","year":"1987","journal-title":"Diabete Metab"},{"key":"e_1_2_9_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802778"},{"key":"e_1_2_9_97_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000080884.27358.49"},{"key":"e_1_2_9_98_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.9.2211"},{"key":"e_1_2_9_99_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01288.x"},{"key":"e_1_2_9_100_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.15.6998"},{"key":"e_1_2_9_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.10.042"},{"key":"e_1_2_9_102_2","first-page":"3527","article-title":"Endothelial cells in physiology and in the pathophysiology of vascular disorders","volume":"91","author":"Cines DB","year":"1998","journal-title":"Blood"},{"key":"e_1_2_9_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-004-2607-z"},{"key":"e_1_2_9_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1742-2"},{"key":"e_1_2_9_105_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.16.7742"},{"key":"e_1_2_9_106_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.14.10.1521"},{"key":"e_1_2_9_107_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:REMD.0000032407.88070.0a"},{"key":"e_1_2_9_108_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.142.1.100"},{"key":"e_1_2_9_109_2","first-page":"1721","article-title":"Production of tumor necrosis factor and interleukin\u20101 by macrophages from human atheromatous plaques","volume":"142","author":"Tipping PG","year":"1993","journal-title":"Am J Pathol"},{"key":"e_1_2_9_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90291-8"},{"key":"e_1_2_9_111_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007263230405"},{"key":"e_1_2_9_112_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116834"},{"key":"e_1_2_9_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90115-L"},{"key":"e_1_2_9_114_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.18.2149"},{"key":"e_1_2_9_115_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.8.2907"},{"key":"e_1_2_9_116_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117899"},{"key":"e_1_2_9_117_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000229685.37402.80"},{"key":"e_1_2_9_118_2","first-page":"RA5","article-title":"Markers of inflammation and coronary artery disease","volume":"8","author":"Saadeddin SM","year":"2002","journal-title":"Med Sci Monit"},{"key":"e_1_2_9_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90137-6"},{"key":"e_1_2_9_120_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01426.x"},{"key":"e_1_2_9_121_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0518"},{"key":"e_1_2_9_122_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.14.1730"},{"key":"e_1_2_9_123_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0255"},{"key":"e_1_2_9_124_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.5.8624"},{"key":"e_1_2_9_125_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.7.1779"},{"key":"e_1_2_9_126_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.6.1595"},{"key":"e_1_2_9_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09335-2"},{"key":"e_1_2_9_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12255-6"},{"key":"e_1_2_9_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91565-8"},{"key":"e_1_2_9_130_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1989.tb24001.x"},{"key":"e_1_2_9_131_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.4.972"},{"key":"e_1_2_9_132_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902113400607"},{"key":"e_1_2_9_133_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.97"},{"key":"e_1_2_9_134_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000130484.20501.df"},{"key":"e_1_2_9_135_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909309046948"},{"key":"e_1_2_9_136_2","doi-asserted-by":"publisher","DOI":"10.1536\/jhj.45.183"},{"key":"e_1_2_9_137_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1989.tb08554.x"},{"key":"e_1_2_9_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(96)05968-0"},{"key":"e_1_2_9_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00066-2"},{"key":"e_1_2_9_140_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050822"},{"key":"e_1_2_9_141_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000020546.30940.92"},{"key":"e_1_2_9_142_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.5.1647"},{"key":"e_1_2_9_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00299-9"},{"key":"e_1_2_9_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.12.010"},{"key":"e_1_2_9_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(03)00140-0"},{"key":"e_1_2_9_146_2","doi-asserted-by":"publisher","DOI":"10.1053\/ejvs.2000.1278"},{"key":"e_1_2_9_147_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2001.060"},{"key":"e_1_2_9_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00250-2"},{"key":"e_1_2_9_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.12.048"},{"key":"e_1_2_9_150_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000257974.06317.49"},{"key":"e_1_2_9_151_2","unstructured":"Trial identifier NCT00094796. Available at:www.ClinicalTrials.gov. Accessed February 25 2006."},{"key":"e_1_2_9_152_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"e_1_2_9_153_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe078099"},{"key":"e_1_2_9_154_2","unstructured":"The Rosiglitazone Story\u2014Lessons from an FDA Advisory Committee Meeting. Available at: N Engl J Med2007.http:\/\/content.nejm.org\/cgi\/content\/full\/NEJMp078167."},{"key":"e_1_2_9_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69420-8"},{"key":"e_1_2_9_156_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_9_157_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1470"},{"key":"e_1_2_9_158_2","unstructured":"EMEA statement on recent publication on cardiac safety of rosiglitazone (Avandia Avandamet Avaglim). Available at:http:\/\/www.emea.europa.eu\/pdfs\/general\/direct\/pr\/2300\u20105707en.pdf. Accessed May 23 2007."},{"key":"e_1_2_9_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60787-9"},{"key":"e_1_2_9_160_2","unstructured":"ACCORD. Available at:http:\/\/www.accordtrial.org\/public\/index.cfm. Accessed May 11 2006."},{"key":"e_1_2_9_161_2","unstructured":"Bypass angioplasty revascularization investigation in type 2 diabetes (BARI 2D). Available at:http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00006305?order=1. Accessed April 27 2007."}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdmrr.790","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:59:57Z","timestamp":1696982397000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,7]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1002\/dmrr.790"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.790","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,7]]}}}